CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS

$598,926R01FY2020CANIH

Hoag Memorial Hospital Presbyterian, Newport Beach CA

Investigators

Gary Allan Ulanercontact Carl Ola Landgren

View original record on NIH RePORTER →

CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS · GrantIndex